linjc16/ctgov huggingface dataset:
Treatment of Severe Heart Failure by Ultrafiltration

Study Overview
=================
Brief Summary
-----------------
Patients with severe congestive heart failure show increased fluid body content which is often resistant to conventional diuretic therapy. Therefore, chronic heart failure patients have frequent access to the emergency room and hospital for hemodynamic instability. Ultrafiltration is a simple renal replacement therapy which reduces fluid overload. The purpose of this study is to determine whether periodic ultrafiltration sessions maintain patients in stable clinical condition and reduce hospitalisations as well as access to emergency heart failure treatment.

Detailed Description
-----------------
Patients with severe heart failure (New York Heart Association [NYHA] III-IV) and fluid overload will be randomized to ultrafiltration (UF group) or conventional medical treatment (Control group). Patients follow-up at least monthly visit for one year. Ultrafiltration will be repeated during follow-up in case of body weight gain due to fluid accumulation. Ultrafiltration will be performed during short term hospitalization.

Official Title
-----------------
Ultrafiltration for the Chronic Treatment of Severe Congestive Heart Failure

Conditions
-----------------
Severe Congestive Heart Failure

Intervention / Treatment
-----------------
* Procedure: ultrafiltration


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Severe heart failure (NYHA III-IV) with fluid overload Ejection fraction < 40% Estimated fluid overload > 4 kg Exclusion Criteria: Severe renal insufficiency Acute pulmonary edema and/or cardiogenic shock

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Ultrafiltration<br>Ultrafiltration treatment | Procedure: ultrafiltration<br> <br> |
| Active Comparator: Usual treatment<br>Usual HF treatment | Procedure: ultrafiltration<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of hospitalizations for heart failure |  | End of study | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| long term major adverse clinical events including death |  | End of study | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ultrafiltration, heart failure, fluid overload
Drains Ablation Post Total Hip Arthroplasty : Search for the Least Painful Technique

Study Overview
=================
Brief Summary
-----------------
Comparison of ablation technique of drains

Official Title
-----------------
Drains Ablation Post Total Hip Arthroplasty : Search for the Least Painful Technique

Conditions
-----------------
Total Hip Arthroplasty, Drain Insertion Site

Intervention / Treatment
-----------------
* Procedure: drain ablation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients admitted to the orthopedic surgery department for surgery for a total hip arthroplasty Signed inform consent form Exclusion Criteria: Drain in non-aspirating mode at the time of medical ablation prescription Administration of analgesic III in the 12 hours preceding the inclusion

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Drain ablation - Non Aspiration mode<br>Drain ablation will be done in non Aspiration mode | Procedure: drain ablation<br>* drain ablation will be done in Aspiration mode or in non Aspiration mode<br>|
| Other: Drain ablation - Aspiration mode<br>Drain ablation will be done in Aspiration mode | Procedure: drain ablation<br>* drain ablation will be done in Aspiration mode or in non Aspiration mode<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluate the pain felt by the patients at the time of the removal of the drain, using the pain visual analogue scale | pain will be measured using a visual analogic scale from 0 (for no pain) to 10 (fo maximum pain) | 20 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Presence of haematoma after ablation | Presence or absence of haematoma will be visually checked | Day 2 post ablation |
COVID-19 and Sports - an Online Survey on the Impact of the Pandemic and Possible Preventive Measures

Study Overview
=================
Brief Summary
-----------------
Aim of the study was to investigate the effects of the COVID-19 pandemic on individual and general sport activities in an effort to provide information for safe return to community sports.

Official Title
-----------------
COVID-19 and Sports - an Online Survey on the Impact of the Pandemic and Possible Preventive Measures

Conditions
-----------------
Covid19

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: -Age over 18 years Exclusion Criteria: age under 18 years

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The type, extent and intensity of physical activity |  | 10 to15 minutes |
Cleveland Clinic Families Get Fit (CCFit) : A Family-based Activity-Monitor Intervention in Pediatric Obesity

Study Overview
=================
Brief Summary
-----------------
This is a randomized prospective study to evaluate the effectiveness of a family-based intervention using activity-monitors (I.e. Fitbits) in children and adolescents aged 8-18 years with a BMI greater than or equal to 95%ile who attend the Cleveland Clinic multidisciplinary Be Well pediatric obesity clinic.

Official Title
-----------------
Cleveland Clinic Families Get Fit (CCFit) : A Family-based Activity-Monitor Intervention in Pediatric Obesity

Conditions
-----------------
Obesity, Childhood

Intervention / Treatment
-----------------
* Behavioral: Family Based Activity Intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Be Well patient Age 8*-18 years BMI > 95%ile English speaking Exclusion Criteria: Uncontrolled asthma Orthopedic or other medical issue limiting mobility Participant has worn an activity-monitor in the past 6 months (ok if parents wear)

Ages Eligible for Study
-----------------
Minimum Age: 8 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Intervention Group<br>3 in-person visit group | Behavioral: Family Based Activity Intervention<br>* Providing youth and their families with access to the knowledge and resources to increase their physical activity will allow them to lead more healthy lifestyles will provide them with the foundation for a healthier life, and future ahead.<br>|
| Active Comparator: Control/Crossover Group<br>5 in-person visit group | Behavioral: Family Based Activity Intervention<br>* Providing youth and their families with access to the knowledge and resources to increase their physical activity will allow them to lead more healthy lifestyles will provide them with the foundation for a healthier life, and future ahead.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Exercise Capacity | 6 minute walk distance | Change from Baseline Six Minute Walk Distance through study completion (up to 33 weeks) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Weight | weight measured in kilograms | Change from Baseline weight through study completion (up to 33 weeks) | 
| Fitbit Data | Steps per Day | Change in steps per day wearing Fitbit and after 1 week Goal Setting Steps | 
| Height | height measured in centimeters | Change from Baseline height through study completion (up to 33 weeks) |
Collection of Liver Tissue for Virologic Studies

Study Overview
=================
Brief Summary
-----------------
This study will examine liver tissue to investigate the role of viral infections in fulminant hepatitis, liver failure, and profound bone marrow failure. All patients who are undergoing liver biopsy or liver transplantation may participate in this study. For patients undergoing liver biopsy, a small piece of liver tissue will be taken from the sample collected during the scheduled biopsy. For patients undergoing liver transplantation, a small piece of tissue will be collected from the diseased liver that is to be removed.

Detailed Description
-----------------
Our laboratory has a long-standing interest in viruses that affect the bone marrow. Many such viruses also may cause hepatitis. One specific syndrome, post-hepatitis aplastic anemia, suggests that the same agent is responsible for both severe and sometimes fulminant hepatitis as well as profound bone marrow failure. In investigating the role of viruses in these diseases, we require small amounts of liver tissue for molecular studies. We request permission to obtain samples from patients undergoing 1) liver transplantation or 2) liver biopsy at the time of surgery for purpose of virus discovery, including obtaining control samples. For liver transplant samples, tissue will be obtained from the removed organ; in other surgical circumstances, small amounts of tissue will be obtained when the liver is biopsied for other medical indications. No additional risk to the patient should result from either procedure.

Official Title
-----------------
Collection of Liver Tissue for Virologic Studies

Conditions
-----------------
Virus Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
All patients undergoing open liver biopsy or the removal of liver for purposes of hepatic transplantation are eligible for participation. There are no exclusion criteria.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Fulminant Hepatitis, Parvovirus, Hepatitis, Biopsy, Control, Liver Biopsy
Prospective Observational Study for Determination of Minimal Clinically Important Difference of Allergic Rhinitis Symptoms Due to Grass Pollen (Equinoxe 2)

Study Overview
=================
Brief Summary
-----------------
Prospective multi-center study carried out in France involving patients with allergic rhinitis. Study in usual care where no specific diagnostic or therapeutic procedure is required. The patients will be asked to fill in Questionnaires on a daily and weekly basis.

Official Title
-----------------
Determination of Minimal Clinically Important Difference of Allergic Rhinitis Symptoms Due to Grass Pollen by the Assessment of the Relationship Between the Symptom Scores and Global Rating of Change Questionnaires on the Quality of Life and Well-being.

Conditions
-----------------
Allergic Rhinitis Due to Grass Pollen

Intervention / Treatment
-----------------
* Other: Allergic rhinitis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female patients aged between 6 and 65 years. Patients who have been informed of the nature and aims of the study and have given their written consent to participate in this study in accordance with local laws and requirements. Patient with an Grass pollen-related allergic rhinitis (immunologically and / or symptomatically treated or non treated). Patients presented for symptomatic management of allergic rhinitis. Patients having Symptoms score ≥ 6. Exclusion Criteria: Patients involved in any other clinical/observational study. patients unable to fill in the study questionnaires. Patient suffering from any diagnosed disease that may interfere with the evaluation of allergic rhinoconjunctivitis' related quality of life, fatigue and daily activities. Patients treated with any drug that may influence the patient's fatigue and/or interfere with psychomotor performance. Patients suffering from persistent asthma, or asthma exacerbation during grass pollen season.

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Allergic rhinitis<br> | Other: Allergic rhinitis<br>* Questionnaire<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rhinitis Total Symptoms Score (RTSS), (intensity of each symptom measured on a 4-point scale) compared to a 15-point global rating of change questionnaire. |  | 6 months per patient |
Sun Protection Factor Assay (SPF Assay 206/2016)

Study Overview
=================
Brief Summary
-----------------
To evaluate the Sun Protection Factor efficacy on human skin.

Official Title
-----------------
Sun Protection Factor (SPF) Assay: UVA Protection Factor Assay Minimal Persistent Pigment-Darkening Dose

Conditions
-----------------
Sunscreening Agents

Intervention / Treatment
-----------------
* Drug: BAY987521


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Fitzpatrick Skin Type l, ll and/or lll for UVB testing. Fitzpatrick Skin Type ll, lll and/or lV for UVA testing. Male and female. Aged between 18-70 years old. Good health as determined from the HRL SHF (Subject History Form). Signed and dated Informed Consent Form. Signed and dated HIPAA (Health Insurance Portability and Accountability Act) form. An unambiguous MED (Minimal Erythema Dose) or MPPD (Minimal Persistent Pigment Darkening Dose) Exclusion Criteria: Subjects on test at any other research laboratory or clinic. Known allergy or sensitivity to sunscreens, cosmetics and toiletries, topical drugs and/or ultraviolet light. Pre-existing dermatologic conditions which have been diagnoses by a medical professional (e.g. psoriasis, eczema, etc.)which would interfere with this study. Pre-existing other medical conditions (e.g. adult asthma, diabetes). Treatment with antihistamines or corticosteroids within one week prior to initiation of the test. Treatment with antibiotics within two weeks prior to initiation of the test. Chronic medication which could affect the results of the study. Known pregnant or nursing women.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: BAY987521<br>Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. | Drug: BAY987521<br>* Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Code:Z09-067)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Minimal Erythema Dose (MED) |  | Up to 15 minutes | 
| Minimal Persistent Pigment Darkening Dose (MPPD) |  | Up to 15 minutes |
Evaluating the Use of a Device Called Impulse Oscillometry in Participants With Vocal Cord Disorders or Asthma

Study Overview
=================
Brief Summary
-----------------
This study will determine if airway resistance to airflow and pressure, measured by Impulse Oscillometry, is impacted in subjects with vocal cord disorders and whether these measurements are different when compared to subjects with asthma.

Official Title
-----------------
The Study of Impulse Oscillometry in Inducible Laryngeal Obstruction

Conditions
-----------------
Breathing, Mouth, Lung Function Decreased, Vocal Cord Dysfunction, Laryngeal Obstruction, Asthma

Intervention / Treatment
-----------------
* Device: Impulse Oscillometer


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Vaccinated against COVID-19 or testing negative for COVID-19 by viral PCT within 5 days before testing Willingness to perform breathing test Must be able to speak and understand English Documented diagnosis of asthma, documented clinical diagnosis of vocal cord dysfunction, or undergoing evaluation for vocal cord dysfunction Exclusion Criteria: Unable to provide consent or perform oscillometry test

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Subjects with a diagnosis of vocal cord dysfunction<br>Subjects with a confirmed or suspected diagnosis of vocal cord dysfunction (also called inducible laryngeal obstruction). Some subjects will have concomitant diagnosis of asthma. | Device: Impulse Oscillometer<br>* The tremoFlo C-100 Airwave Oscillometry System is intended to measure respiratory system impedance using the Forced Oscillation Technique (FOT).<br>* Other names: THORASYS tremoFlo C-100 Airwave Oscillometry System;|
| Subjects with diagnosis of asthma<br>Subjects with physician-diagnosed asthma. Some subjects will have concomitant diagnosis of vocal cord dysfunction. | Device: Impulse Oscillometer<br>* The tremoFlo C-100 Airwave Oscillometry System is intended to measure respiratory system impedance using the Forced Oscillation Technique (FOT).<br>* Other names: THORASYS tremoFlo C-100 Airwave Oscillometry System;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean respiratory system impedance | The oscillometer will collect an airway impedance measurement which is made up of multiple variables. | Single measurement, approximately day 1 |
Cardiovascular Variability and Heart Rate Response Associated With Obstructive Sleep Apnea

Study Overview
=================
Brief Summary
-----------------
Obstructive sleep apnea is often associated with microarousals and a stimulation of the sympathetic nervous system. The knowledge of this autonomic activation may help understanding the increase of cardiac risk observed in elderly. The aim of the study is to evaluate the relationship between obstructive sleep apnea severity, age, gender and heart rate response associated with obstructive sleep apnea. Drug-free patients diagnosed with obstructive sleep apneas were included. Clinical data and 24-h polysomnography recordings were analyzed.

Official Title
-----------------
Cardiovascular Variability and Heart Rate Response Associated With Obstructive Sleep Apnea

Conditions
-----------------
Sleep Apnea, Obstructive

Intervention / Treatment
-----------------
* Device: standard 24-h ambulatory polysomnography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Restless legs syndrome patients Hospital routine for sleep disorders breathing diagnosis Apnea index > 0 Exclusion Criteria: Narcolepsy-cataplexy Sleep irregularities and sleep deprivation symptoms Lack of neurological or psychiatric diseases Periodic leg movements Central sleep apnea, treatment Cerebral lesion Medical illness Medication or drinks affecting sleep and wake state.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| patients with obstructive sleep apneas<br> | Device: standard 24-h ambulatory polysomnography<br>* A standard 24-h ambulatory ad libitum polysomnography including EEG, electro-oculography (EOG), electromyography (EMG), EKG, was performed by a standard clinical.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Amplitude of heart rate response associated with obstructive sleep apneas | standard 24-h ambulatory ad libitum polysomnography | At diagnosis | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Other Heart rate variability indices: Ptot | standard 24-h ambulatory ad libitum polysomnography | At diagnosis | 
| Other Heart rate variability indices: very-low-frequency (VLF), low frequency (LF), low frequency normalized units (LFnu), high-frequency normalized units (HFnu) | standard 24-h ambulatory ad libitum polysomnography | At diagnosis | 
| Other Heart rate variability indices: LF/HF | standard 24-h ambulatory ad libitum polysomnography | At diagnosis | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Obstructive sleep apnea, Heart rate, Heart rate variability, Microarousals, Autonomic nervous system activity